Rheumatic arthritis treatment traditional Chinese medicine containing embelia parviflora and preparation method of rheumatic arthritis treatment traditional Chinese medicine

Abstract

The invention relates to the field of traditional Chinese medicines, and discloses an embelia parviflora-containing traditional Chinese medicine for treating rheumatic arthritis and a preparation method of the embelia parviflora-containing traditional Chinese medicine. 10-20 parts of radix achyranthis bidentatae; 10-20 parts of ligusticum wallichii; 10-20 parts of radix paeoniae alba; 5-10 parts of fructus lycii; 5-10 parts of radix rehmanniae recen; the preparation method comprises the following steps: crushing embelia parviflora, radix achyranthis bidentatae, ligusticum wallichii, radix paeoniae alba, fructus lycii and radix rehmanniae recen; extracting medicinal components of the medicinal materials; the extracting solution is mixed with phospholipid or a polymer to form liposome, and the liposome is pH response type nano-liposome or temperature response type nano-liposome; preparing nano-liposome by a film hydration method or a layer-by-layer self-assembly method; and filtering and drying to obtain the traditional Chinese medicine. By using the pH response type nano-liposome and the temperature response type nano-liposome, the medicine can be accurately released to an inflammation area, the medicine is ensured to be only released at a place needing to be treated, and the treatment effect is improved.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating rheumatoid arthritis containing angelica vine and a preparation method thereof. Background Art

[0002] In modern medicine, rheumatoid arthritis (RA) is a common chronic immune disease, which is mainly manifested by inflammation, swelling and pain in the joints, seriously affecting the quality of life of patients. Although there are many drugs for the treatment of rheumatoid arthritis, the existing treatment methods still have some significant shortcomings, especially in the drug delivery system. Traditional drug delivery methods, such as oral, topical or injection methods, usually face the problems of poor drug targeting, unstable drug release rate, and failure of drugs to accurately reach the site of inflammation. Most drugs have large individual differences in absorption, distribution and metabolism in the body, and most drugs are easily metabolized or degraded when passing through the liver or intestinal barrier, resulting in weakened efficacy or increased side effects. In addition, although the existing nano drug delivery system has made certain progress in some aspects, it still has problems such as difficulty in accurately controlling the drug release rate and difficulty in continuous and stable drug release. In particular, the drug release process of some traditional nano liposomes mainly depends on the physical properties of the carrier, such as particle size, surface charge, etc. These factors are often unable to be accurately adjusted in the complex in vivo environment, resulting in unstable drug release during the release process and inability to achieve long-term and sustained therapeutic effects. When treating rheumatoid arthritis, drugs must be released continuously and stably, and reach the lesion area precisely to reduce side effects and improve efficacy. Traditional drug delivery systems often fail to solve this problem. Drugs are distributed throughout the body and fail to effectively target the site of inflammation, which makes it impossible to fully exert their efficacy, resulting in unsatisfactory treatment results. Summary of the invention

[0003] In view of the shortcomings of the prior art, the present invention provides a Chinese medicine for treating rheumatoid arthritis containing Angelica suspensa and a preparation method thereof, which solves the problems in the prior art of poor drug targeting, unstable drug release rate, and failure of the drug to accurately reach the site of inflammation.

[0004] To achieve the above objectives, the present invention is implemented by the following technical scheme: A Chinese medicine for treating rheumatoid arthritis containing Angelica sinensis vine, comprising the following components by mass:

[0005] 30-50 parts of Angelica sinensis vine;

[0006] 10-20 servings of Achyranthes bidentata;

[0007] 10-20 parts of Chuanxiong;

[0008] 10-20 parts of white peony root;

[0009] 5-10 servings of wolfberry;

[0010] 5-10 portions of raw Rehmannia root.

[0011] A method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica sinensis vine, comprising the following steps:

[0012] Crush angelica vine, Achyranthes bidentata, Chuanxiong, White Peony Root, Lycium barbarum and Rehmannia root;

[0013] Extracting medicinal components from the above medicinal materials;

[0014] The extract is mixed with phospholipids or polymers to form liposomes, wherein the liposomes are pH-responsive nanoliposomes or temperature-responsive nanoliposomes;

[0015] Nanoliposomes were prepared by thin film hydration method or layer-by-layer self-assembly method;

[0016] The Chinese medicine for treating rheumatoid arthritis containing angelica vine is obtained by filtering and drying.

[0017] Preferably, the pH-responsive nanoliposomes are prepared by a thin film hydration method, and the surface of the liposomes is modified with polyvinyl alcohol or polyacrylate.

[0018] Preferably, the temperature-responsive nanoliposome is prepared by a layer-by-layer self-assembly method, and the outer layer of the liposome is a temperature-responsive polymer PNIPAM.

[0019] Preferably, the drug loading of the nanoliposomes is 1-5% (w / v).

[0020] Preferably, the pulverized particle size of the medicinal material is 30-50 mesh.

[0021] Preferably, the particle size of the nanoliposome is controlled at 100-200 nm.

[0022] Preferably, the extraction time of the extract is 30-60 minutes and the extraction temperature is 40-60°C.

[0023] A Chinese medicine preparation for treating rheumatoid arthritis is prepared by preparing the Chinese medicine for treating rheumatoid arthritis containing angelica vine as claimed in claim 1 into pills or tablets.

[0024] Preferably, the Chinese medicine preparation is used for preparing a drug for treating rheumatoid arthritis.

[0025] The present invention provides a Chinese medicine for treating rheumatoid arthritis containing angelica vine and a preparation method thereof. The medicine has the following beneficial effects:

[0026] 1. The present invention uses pH-responsive and temperature-responsive nanoliposomes to enable the drug to be accurately released into the inflammatory area. Compared with the conventional drugs in the prior art that directly enter the body, the efficacy is unstable or the drug is difficult to accurately reach the lesion, the present invention can ensure that the drug is released only where treatment is needed, thereby improving the therapeutic effect.

[0027] 2. The present invention controls the amount and speed of drug release by optimizing the preparation method of liposomes. Compared with the prior art where drugs are easily released prematurely or the effects disappear, the present invention can continuously release drugs, ensuring that the drugs maintain therapeutic effects for a long time, reducing the trouble of patients needing to take drugs frequently.

[0028] 3. The present invention uses responsive materials to ensure that the drug is released in the lesion area and maintains a certain effect. Compared with the existing technology, the drug can act more accurately on the onset site of rheumatoid arthritis during the treatment process, reducing the impact on other healthy areas, making the treatment more efficient and direct. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is a schematic diagram of the preparation process of the present invention. DETAILED DESCRIPTION

[0030] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] Example 1: Preparation of pH-responsive nanoliposomes

[0032] Please refer to the attached Figure 1 , steps and process parameters:

[0033] Take Angelica sinensis vine (35 parts), Achyranthes bidentata (15 parts), Ligusticum chuanxiong (12 parts), White Peony Root (12 parts), Lycium barbarum (7 parts) and Rehmannia root (6 parts), and crush them into 30 mesh size to ensure that the active ingredients of the medicinal materials can be fully released.

[0034] Using ultrasonic extraction, the powdered medicinal material was mixed with 60% ethanol solution at a ratio of 1:5, the extraction time was 40 minutes, and the extraction temperature was set at 50°C. After obtaining the extract, it was filtered and concentrated.

[0035] Phospholipids (15 g) and polyacrylate (5 g) were dissolved in dichloromethane, and the solvent was removed by rotary evaporation to form a lipid film. Then, the extract solution (pH 4.8 hydration solution) was added for hydration, the temperature was set to 50 ° C, and the hydration time was 60 minutes. This step ensures that the active ingredients of the drug are encapsulated in the liposomes.

[0036] The liposomes were dispersed by ultrasonic treatment to stabilize the particle size between 100-200 nanometers. The drug loading was 2.5% (w / v), ensuring that the liposomes could stably carry the drug and release it locally.

[0037] The liposomes without drug encapsulation were removed by 0.22 μm filtration to ensure the purity of the preparation. The final drug preparation was stored at -20°C to ensure its stability.

[0038] Embodiment 2:

[0039] Steps and process parameters:

[0040] Take Angelica sinensis vine (40 parts), Achyranthes bidentata (18 parts), Ligusticum chuanxiong (15 parts), White Peony Root (12 parts), Lycium barbarum (6 parts) and Rehmannia root (9 parts), and grind them into 40 mesh.

[0041] Using the maceration extraction method, the medicinal material was soaked in 70% ethanol at a ratio of 1:6 for 50 minutes, and then filtered and concentrated to obtain the medicinal solution.

[0042] Phospholipids (10 g) and PNIPAM (2 g) were dissolved in chloroform (20 ml), and the solvent was removed by rotary evaporation to form a lipid film. Then, the extract (pH 5.0 hydration solution) was added for hydration, and the hydration temperature was set at 60 ° C and the hydration time was 60 minutes to ensure that the liposomes could evenly encapsulate the drug components.

[0043] The layer-by-layer self-assembly method was used to gradually add different polymer layers to finally obtain 150nm nanoliposomes. The drug loading was controlled at 3% (w / v).

[0044] The drug release rate was tested at 32°C and 37°C. At 37°C, PNIPAM undergoes a phase transition and drug release is accelerated. The test results show that increasing the temperature can significantly increase the drug release rate.

[0045] After filtering through a 0.22 μm filter membrane, the liposomes were stored at low temperatures to ensure their stability.

[0046] Embodiment 3:

[0047] Steps and process parameters:

[0048] Crush Angelica sinensis vine (50 parts), Achyranthes bidentata (10 parts), Ligusticum chuanxiong (10 parts), White Peony Root (10 parts), Lycium barbarum (5 parts) and Rehmannia root (5 parts) into 40 mesh.

[0049] Using ultrasonic extraction method, the medicinal materials were mixed with 60% ethanol solution in a ratio of 1:5, the extraction time was 45 min, the extraction temperature was 50°C, and then the extract was filtered and concentrated.

[0050] Using the thin film hydration method, phospholipids (10 g) and polyvinyl alcohol (5 g) were dissolved in chloroform and rotary evaporated to form a thin film. Extraction solution (pH 5.5 hydration solution) was added for hydration. The temperature during the hydration process was set at 50°C and the time was 45 minutes.

[0051] The particle size was controlled within 120 nm by ultrasonic treatment and high-pressure homogenization, and the drug loading was 3.0% (w / v) to ensure uniform drug distribution.

[0052] The final preparation was obtained by filtering with a 0.22 μm filter membrane to remove the liposomes without drug encapsulation and stored at low temperature.

[0053] Embodiment 4:

[0054] Steps and process parameters:

[0055] Crush Angelica sinensis vine (40 parts), Achyranthes bidentata (15 parts), Ligusticum chuanxiong (12 parts), White Peony Root (10 parts), Fructus Lycii (8 parts) and Radix Rehmanniae (5 parts) into 50 mesh.

[0056] The traditional decoction method was adopted, the medicinal materials and water were decocted at a ratio of 1:6 for 60 minutes, the decoction was taken, filtered and concentrated to obtain a concentrated solution.

[0057] The concentrate is dried by spray drying to form granular drugs, and finally formed into tablets by tablet compression.

[0058] Example 5: Comparison of conventional and responsive liposome preparation

[0059] Steps and process parameters:

[0060] Crush Angelica sinensis vine (30 parts), Achyranthes bidentata (10 parts), Ligusticum chuanxiong (15 parts), White Peony Root (10 parts), Lycium barbarum (8 parts) and Rehmannia root (7 parts) into 50 mesh.

[0061] The ultrasonic extraction method was used, the extracting solution was 50% ethanol, the extraction ratio was 1:6, the extraction time was 40 minutes, and the temperature was 45°C to obtain the medicinal solution.

[0062] Liposomes were prepared using conventional phospholipids (10 g) and polyvinyl alcohol (5 g) by the thin film hydration method without using responsive materials.

[0063] Comparative experiment 1: Traditional preparation method vs pH-responsive nanoliposomes

[0064] Comparison conditions:

[0065] Traditional preparation method:

[0066] After the medicinal materials are crushed, the medicinal liquid is extracted using the traditional decoction method, the medicinal liquid is dried into particles by the spray drying method, and the medicine is made into a tablet by the tablet pressing method.

[0067] The drug was used via conventional tablet preparation methods with a drug loading of 5% (w / v), but no nanoliposome technology was used and no modification with responsive materials was performed.

[0068] pH-responsive nanoliposomes:

[0069] Liposomes are prepared using thin film hydration and pH-responsive polymers (such as polyacrylates). The drug loading is controlled to 2.5% (w / v) and the liposome particle size is controlled in the range of 100-200nm to ensure that the drug is released in a local acidic environment, achieving higher targeting and therapeutic effects.

[0070] the difference:

[0071] Traditional methods cannot achieve precise drug release, the bioavailability of drugs is low, and the therapeutic effect is unstable. In contrast, pH-responsive liposomes can ensure that drugs are released in a local acidic environment, improving the targeting and efficacy of drugs.

[0072] Comparative experiment 2: No responsive polymer vs. temperature-responsive nanoliposomes

[0073] Comparison conditions:

[0074] Without using responsive polymer:

[0075] The drug was prepared into liposomes using conventional phospholipids and polyvinyl alcohol. The particle size was controlled at 300nm and the drug loading was 3% (w / v). There was no adjustment for temperature changes and the drug release process was relatively stable, but it could not be precisely adjusted.

[0076] Temperature-responsive nanoliposomes:

[0077] The liposomes were prepared by layer-by-layer self-assembly using temperature-responsive polymers such as PNIPAM, with a particle size of 150nm and a drug loading of 3% (w / v). When the local temperature rises, the liposomes can undergo a phase transition, promoting drug release.

[0078] the difference:

[0079] The drug release of liposomes without responsive polymers cannot be adjusted with temperature changes, the drug effect is relatively stable, and it does not have the advantage of precise release in local areas. Temperature-responsive nanoliposomes can better control the release rate of drugs in the inflammatory area and increase the therapeutic effect.

[0080] Comparative experiment 3: Traditional drug loading vs. drug loading of the present invention

[0081] Comparison conditions:

[0082] Traditional drug loading:

[0083] The drug loading amount is usually 5% (w / v), and the drug is loaded through traditional tablet or granule preparation methods. However, the common disadvantages of this method are uneven distribution of the drug in the body and too rapid release of the drug, which affects the efficacy.

[0084] The drug loading of the present invention is:

[0085] The drug loading is controlled in the range of 2.5%-3% (w / v), and precise drug delivery is carried out through pH-responsive or temperature-responsive nanoliposomes to ensure that the drug can be effectively released in a specific area within the required time.

[0086] the difference:

[0087] Traditional drug loading is high, but the drug is released too quickly, resulting in discontinuous treatment effects and even drug waste. The present invention controls the drug loading to ensure the sustained release of the drug at an appropriate concentration, thereby improving the treatment effect and bioavailability.

[0088] Comparative experiment 4: Traditional particle size control vs. nanoliposome particle size control

[0089] Comparison conditions:

[0090] Traditional particle size control:

[0091] The particle size of drugs is usually large, controlled at around 300 nm. Liposomes with larger particle sizes may cause immune responses in the body or be quickly cleared by organs such as the liver and spleen, reducing the bioavailability and targeting of the drug.

[0092] Nanoliposome particle size control:

[0093] The present invention adopts ultrasonic treatment and high-pressure homogenization method to accurately control the particle size of liposomes within the range of 100-200nm, and such particle size is conducive to improving the permeability and intake efficiency of drugs.

[0094] the difference:

[0095] Traditionally, the particle size is controlled to be large, and the drug may be excreted prematurely or unevenly distributed in the body. However, the nanoliposome particle size controlled by the present invention can effectively penetrate into the inflammatory site, increase the efficacy of the drug, and reduce the impact on other healthy tissues.

[0096] Comparative experiment 5: Traditional drug release rate vs. responsive drug release of the present invention

[0097] Comparison conditions:

[0098] Traditional drug release rate:

[0099] When drugs are delivered via conventional pharmaceutical formulations, the release rate is usually linear, with the drug being released rapidly over a short period of time, followed by a decrease in efficacy, resulting in a short-lasting therapeutic effect.

[0100] Responsive drug release of the present invention:

[0101] The pH-responsive or temperature-responsive liposome of the present invention can adjust the release rate of the drug according to the acidity or temperature change of the lesion area. In the inflammatory area, the drug release is accelerated to provide a sustained therapeutic effect.

[0102] the difference:

[0103] The release rate of traditional drugs cannot be adjusted according to changes in the lesion environment, and the therapeutic effect is limited. In contrast, the present invention can accurately adjust the drug release to ensure that the drug effect remains stable during the treatment.

[0104] Experimental design:

[0105] This experiment aims to verify the effect of the present invention by comparing different drug delivery systems and methods in the embodiments of the present invention and comparative experiments, and further prove its innovation and practical application effect. All experiments will follow a strict single-factor comparative design to ensure the reliability and comparability of the experimental results.

[0106] Experiment 1: Comparison of drug release rates

[0107] Purpose:

[0108] The difference in drug release rate between pH-responsive nanoliposomes and conventional nanoliposomes was verified, further demonstrating the precise release effect of the drug in the present invention under specific conditions.

[0109] Experimental setup:

[0110] Experimental Group:

[0111] The pH-responsive nanoliposomes prepared in Example 1 were used, with a drug loading of 2.5% (w / v), a particle size of 150 nm, and a hydration liquid pH of 4.8.

[0112] Comparison group:

[0113] Using the traditional drug delivery method in comparative experiment 1, conventional phospholipid liposomes were prepared with a drug loading of 5% (w / v), a particle size of 300 nm, and a hydration liquid pH of 7.4.

[0114] Experimental methods:

[0115] The above two groups of samples were added into simulated solutions with different pH values ​​(pH 4.8 and pH 7.4) respectively, and the temperature was set at 37°C for the experiment to simulate the in vivo environment.

[0116] At predetermined time points (e.g., 1 h, 3 h, 6 h, and 12 h), samples were taken and the drug concentration was determined by UV-Vis spectrophotometer.

[0117] Draw a drug release curve and compare the drug release amounts at different time points.

[0118] Comparison table:

[0119] Time (hours) Example 1 (pH-responsive nanoliposomes) Drug release (%) Comparative experiment 1 (traditional liposomes) drug release (%) 1 25% 5% 3 45% 20% 6 70% 40% 12 85% 60%

[0120] Expected results:

[0121] The pH-responsive nanoliposome of the present invention undergoes a protonation reaction in an acidic environment, resulting in rapid drug release. Compared with traditional liposomes, the drug release is faster and more concentrated in the initial stage.

[0122] The drug release rate of traditional liposomes in a neutral environment is slow and uniform, and the effect is not as precise as the solution of the present invention.

[0123] Experiment 2: Comparison of temperature-responsive drug release

[0124] Purpose:

[0125] Verify the drug release effect of temperature-responsive nanoliposomes and liposomes without responsive materials in comparative experiment 2 when the temperature rises.

[0126] Experimental setup:

[0127] Experimental Group:

[0128] The temperature-responsive nanoliposomes in Example 2 were used, with a drug loading of 3% (w / v), a particle size of 150 nm, and PNIPAM as the responsive polymer.

[0129] Comparison group:

[0130] The ordinary polymer liposomes in comparative experiment 2 were used, with a drug loading of 3% (w / v), a particle size of 300 nm, and no temperature-responsive polymer.

[0131] Experimental methods:

[0132] The above two groups of samples were placed in an environment of 32°C and 37°C respectively to simulate the temperature changes of rheumatoid arthritis lesions.

[0133] Samples were taken at regular intervals, and the drug concentration was determined using a UV-visible spectrophotometer, and the drug release curve was plotted.

[0134] Compare the drug release rates under temperature changes.

[0135] Comparison table:

[0136] Time (hours) Example 2 (Temperature-responsive nanoliposomes, 37°C) Drug release (%) Comparative experiment 2 (conventional liposomes, 37°C) drug release (%) 1 30% 10% 3 55% 25% 6 80% 50% 12 95% 65%

[0137] Expected results:

[0138] The temperature-responsive nanoliposomes in Example 2 can rapidly release drugs at 37° C., reflecting its temperature-responsive characteristics.

[0139] The release rates of the common liposomes in the control group at 32°C and 37°C were almost the same, lacking temperature responsiveness, and the release rate was relatively stable. The therapeutic effect of the drug was not as obvious as that in Example 2.

[0140] Experiment 3: Comparison of particle size and drug permeability

[0141] Purpose:

[0142] The differences in drug permeability and targeting between the nanoliposomes with controlled particle sizes in the present invention and traditional liposomes were verified, proving that the present invention can better achieve targeted release of drugs in rheumatoid arthritis.

[0143] Experimental setup:

[0144] Experimental Group:

[0145] The nanoliposomes in Example 3 were used, with a particle size of 120 nm and a drug loading of 3% (w / v), and the particle size was controlled by ultrasonic treatment and high-pressure homogenization.

[0146] Comparison group:

[0147] The conventional liposomes used in comparative experiment 3 had a particle size of 300 nm and a drug loading of 5% (w / v), and no particle size optimization was performed.

[0148] Experimental methods:

[0149] The above two groups of samples were injected into the rheumatoid arthritis mouse model to observe the drug's penetration ability in the joint tissue.

[0150] Using tissue sectioning technology, joint tissue is cut and the distribution of the drug in the tissue is observed under a microscope.

[0151] The cumulative concentration of drugs in joint tissues was calculated and statistically analyzed.

[0152] Comparison table:

[0153] Group Particle size (nm) Drug permeability (accumulated concentration in joint tissue, μg / g) Example 3 (Nanoliposomes) 120 15.6 Comparative experiment 3 (traditional liposomes) 300 8.2

[0154] Expected results:

[0155] The particle size of the nanoliposomes in Example 3 is controlled at 120 nm, which can more effectively penetrate into the joint area, and the cumulative concentration of the drug in the joint area is higher.

[0156] The particle size of traditional liposomes is relatively large, the drug permeability is relatively poor, and they fail to effectively accumulate in the joint area, and the therapeutic effect is significantly lower than that of the present invention.

[0157] Experiment 4: Comparison of drug loading

[0158] Purpose:

[0159] The differences in drug release and therapeutic effect between the optimized drug loading amount in the present invention and the traditional drug loading amount were verified.

[0160] Experimental setup:

[0161] Experimental Group:

[0162] Using the nanoliposomes in Example 3, the drug loading was 3% (w / v), the particle size was controlled at 120 nm, and the effective drug release was 2.5% (w / v).

[0163] Comparison group:

[0164] Using traditional liposomes in comparative experiment 3, the drug loading was 5% (w / v), the particle size was 300 nm, and the drug was released too quickly.

[0165] Experimental methods:

[0166] The drug preparation is applied to the rheumatoid arthritis animal model by oral or topical administration.

[0167] Samples were taken regularly to measure the drug concentrations in serum and joint fluid, and a curve showing the change in drug concentration over time was drawn.

[0168] Observe the reduction of inflammation in the joints and the therapeutic effect, and record the duration of the drug's efficacy.

[0169] Comparison table:

[0170] Drug loading (w / v) Example 3 Effective drug release (%) Comparative experiment 3 Effective drug release (%) Treatment effect (inflammation reduction rate, %) 2.5% 80% 50% 80% 5% 75% 90% 50%

[0171] Expected results:

[0172] The optimized drug loading in Example 3 can ensure the sustained release of the drug and maintain the effective concentration for a long time, making the therapeutic effect more stable.

[0173] The 5% drug loading in the control group resulted in too fast drug release, a short duration of therapeutic effect, and a less stable drug effect than the present invention.

[0174] Summarize

[0175] This experimental design verifies the innovation of the present invention through single factor comparison, especially the significant effects of pH-responsive nanoliposomes and temperature-responsive nanoliposomes on drug release, permeability, particle size control and loading optimization. By comparing with traditional drug delivery systems, the advantages of the present invention in improving drug targeting, bioavailability and therapeutic effect can be clearly demonstrated.

[0176] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A Chinese medicine for treating rheumatoid arthritis containing Angelica sinensis vine, characterized in that: Contains the following components by mass: 30-50 parts of Angelica sinensis vine; 10-20 servings of Achyranthes bidentata; 10-20 parts of Chuanxiong; 10-20 parts of white peony root; 5-10 servings of wolfberry; 5-10 portions of raw Rehmannia root.

2. A method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica sphenanthera vine, according to claim 1, characterized in that: The following steps are involved: Crush angelica vine, Achyranthes bidentata, Chuanxiong, White Peony Root, Lycium barbarum and Rehmannia root; Extracting medicinal components from the above medicinal materials; The extract is mixed with phospholipids or polymers to form liposomes, wherein the liposomes are pH-responsive nanoliposomes or temperature-responsive nanoliposomes; Nanoliposomes were prepared by thin film hydration method or layer-by-layer self-assembly method; The Chinese medicine for treating rheumatoid arthritis containing angelica vine is obtained by filtering and drying.

3. The method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica striata vine according to claim 2, characterized in that: The pH-responsive nanoliposome is prepared by a thin film hydration method, and the surface of the liposome is modified by polyvinyl alcohol or polyacrylate.

4. The method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica striata vine according to claim 2, characterized in that: The temperature-responsive nanoliposome is prepared by a layer-by-layer self-assembly method, and the outer layer of the liposome is a temperature-responsive polymer PNIPAM.

5. The method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica striata vine according to claim 2, characterized in that: The drug loading of the nanoliposomes is 1-5% (w / v).

6. The method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica striata vine according to claim 2, characterized in that: The pulverized particle size of the medicinal material is 30-50 meshes.

7. The method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica striata vine according to claim 2, characterized in that: The particle size of the nanoliposome is controlled at 100-200 nm.

8. The method for preparing a Chinese medicine for treating rheumatoid arthritis containing Angelica striata vine according to claim 2, characterized in that: The extraction time of the extract is 30-60 minutes, and the extraction temperature is 40-60°C.

9. A Chinese medicine preparation for treating rheumatoid arthritis, characterized in that: The Chinese medicine for treating rheumatoid arthritis containing angelica vine as claimed in claim 1 is prepared into pills or tablets.

10. A Chinese medicine preparation for treating rheumatoid arthritis according to claim 9, characterized in that: The traditional Chinese medicine preparation is used for preparing medicine for treating rheumatoid arthritis.

Images